ArticleInternational journal of clinical and experimental pathology2015
Downregulation of survivin inhibits proliferation and migration of human gastric carcinoma cells.
Article in International journal of clinical and experimental pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 13 citations in OpenAlex.
- Anti-EpCAM functionalized graphene oxide vector for tumor targeted siRNA delivery and cancer therapy.Asian journal of pharmaceutical sciences · 2021Article
- hnRNPA2B1 regulates the alternative splicing of BIRC5 to promote gastric cancer progression.Cancer cell international · 2021Article
- Article
- The role of survivin in the progression of pancreatic ductal adenocarcinoma (PDAC) and a novel survivin-targeted therapeutic for PDAC.PloS one · 2020Article
- Evaluation of immunohistochemical expression of survivin and its correlation with -31G/C gene polymorphism in colorectal cancer.Medical molecular morphology · 2019Article
- Loss of Sirtuin 1 Alters the Secretome of Breast Cancer Cells by Impairing Lysosomal Integrity.Developmental cell · 2019Article
- Tumor promoter role of miR‑647 in gastric cancer via repression of TP73.Molecular medicine reports · 2018Article
- Construction of a novel vector expressing Survivin-shRNA and fusion suicide gene yCDglyTK and its application in inhibiting proliferation and migration of colon cancer cells.Experimental and therapeutic medicine · 2017Article
- Inhibition of the H3K9 methyltransferase G9A attenuates oncogenicity and activates the hypoxia signaling pathway.PloS one · 2017Article
- Hydroxyflavanone inhibits gastric carcinoma MGC-803 cell proliferation.International journal of clinical and experimental medicine · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer is the second leading cause of cancer-related death worldwide. Survivin overexpressed in many human cancers as a member of the inhibitor of apoptosis protein family. We found that all samples of normal gastric tissues did not express the protein of survivin, and however, 65% human gastric cancer samples expressed survivin. Positive expression of survivin correlated with differentiation. The proliferation and migration of gastric cancer decreased after downregulation of surviving by RNA interference. Furthermore, downregulation of survivin caused the cell cycle arrest. These suggest that survivin play an important role in gastric cancer and the use of survivin siRNA might become an effective approach to cancer therapy.
Indexed as
Identifiers
25973061PMC4396289W213171082What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.